# Precision Medicine & Genomics (Oncology)

**Project Bible | Snowflake Data Cloud, Snowpark, Streamlit**

**Version:** 1.0

**Last updated:** 2026-01-29

## 1. Executive Summary and Strategic Vision

This Project Bible defines the end-to-end architecture, governance model, and analytical capabilities for a Precision Medicine and Genomics analytics platform focused on Oncology. Built on the Snowflake Data Cloud with Snowpark and Streamlit, the platform enables scalable, secure integration of genomic, clinical, and outcomes data to support personalized treatment decisions, translational research, and operational excellence in cancer care.

The strategic vision is to move from siloed genomic reports and retrospective cohort studies toward a continuously learning oncology ecosystem. By integrating next-generation sequencing (NGS) outputs with longitudinal EHR data, pathology results, and treatment outcomes, the organization can operationalize precision oncology at scale while maintaining strict regulatory and ethical controls.

## 2. Strategic Objectives

* **Personalized Treatment Enablement**

  * Match patients to targeted therapies, immunotherapies, and clinical trials based on molecular profiles and clinical context.
* **Clinical Decision Acceleration**

  * Reduce turnaround time from biopsy to actionable insight by integrating genomic pipelines with real-time clinical workflows.
* **Translational Research and Learning Health System**

  * Enable rapid hypothesis testing across cohorts to identify novel biomarkers, resistance patterns, and outcome predictors.
* **Operational and Cost Optimization**

  * Monitor sequencing utilization, test redundancy, and assay performance to reduce unnecessary genomic spend.
* **Regulatory and Ethical Compliance**

  * Ensure compliant handling of genomic data under HIPAA, GDPR (where applicable), and emerging genomic privacy standards.

## 3. Success Criteria and KPIs

* Median time from specimen collection to molecular report reduced by X percent.
* Percentage of oncology patients with guideline-aligned molecular testing above defined threshold.
* Increase in actionable variant detection rate for eligible tumor types.
* Time to therapy selection decision reduced relative to baseline tumor board workflows.
* Zero critical compliance findings related to genomic data access or lineage.

## 4. Scope and Boundaries

* **Included**: Somatic and germline NGS results, variant annotations, pathology metadata, oncology EHR data, treatment regimens, outcomes, and clinical trial matching.
* **Excluded**: Raw sequencer signal processing (handled upstream by bioinformatics pipelines), direct-to-consumer genomics, and non-oncology precision medicine domains (future phase).

## 5. Stakeholders and Roles

* **Executive Sponsor**: Chief Medical Officer or Chief Research Officer
* **Clinical Leadership**: Medical Oncology, Hematology, Molecular Tumor Board
* **Research**: Translational Research, Bioinformatics
* **Laboratory**: Molecular Pathology, Genomics Lab Operations
* **Data & Security**: Data Engineering, Information Security, Privacy Office
* **Deliverable Owners**: BI Engineer, Bioinformatics Engineer, Data Scientist, Streamlit Frontend Lead

## 6. Canonical Oncology Data Milestones

To ensure consistent analytics, the following milestones define the molecular oncology lifecycle:

* **S0 - Specimen Collection**: Biopsy or surgical sample collected.
* **S1 - Specimen Accessioning**: Sample logged into LIMS with metadata.
* **S2 - Sequencing Complete**: NGS run completed.
* **S3 - Variant Calling Finalized**: Bioinformatics pipeline produces VCF output.
* **S4 - Annotation Complete**: Variants enriched with clinical significance databases.
* **S5 - Molecular Report Signed**: Pathologist-approved molecular report.
* **S6 - Treatment Decision**: Therapy selected or clinical trial referral made.
* **S7 - Outcome Observation**: Response, progression, or adverse event recorded.

## 7. High-Level Architecture

* **Cloud Data Platform**: Snowflake Data Cloud with Bronze, Silver, Gold layers.
* **Processing**: Snowpark (Python) for variant normalization, cohort logic, and ML.
* **Ingestion**: Snowpipe for genomic files, annotations, and lab metadata.
* **Presentation**: Streamlit applications for tumor boards, clinicians, and researchers.
* **Interoperability**: FHIR Genomics, HL7, and structured pathology feeds.

## 8. Phase-by-Phase Implementation

### Phase 1: Discovery and Governance Alignment

* Identify priority cancer types and assays.
* Define actionable variant criteria aligned to NCCN or internal guidelines.
* Establish genomic data governance, consent, and secondary use policies.

### Phase 2: Bronze Layer - Genomic and Clinical Ingestion

* Ingest VCF, JSON, or Parquet outputs from upstream pipelines.
* Land annotation feeds from knowledge bases and commercial vendors.
* Preserve immutable raw data for re-annotation as guidelines evolve.

```sql
CREATE OR REPLACE PIPE BRONZE.GENOMICS_INGEST_PIPE
AUTO_INGEST = TRUE
AS
COPY INTO BRONZE.RAW_GENOMIC_FILES
FROM @EXT_STAGE/GENOMICS/
FILE_FORMAT = (TYPE = 'PARQUET')
ON_ERROR = 'SKIP_FILE';
```

### Phase 3: Silver Layer - Normalization and Annotation

* Parse and normalize variants to a canonical schema (gene, locus, consequence).
* Join with annotation sources (clinical significance, drug associations).
* De-identify patient identifiers using irreversible hashing.

```sql
CREATE OR REPLACE TABLE SILVER.STG_VARIANTS AS
SELECT
  v:patient_id_hash::string AS patient_id,
  v:gene::string AS gene,
  v:variant::string AS variant,
  v:clinical_significance::string AS significance,
  v:tumor_type::string AS tumor_type,
  v:reported_at::timestamp AS reported_at
FROM BRONZE.RAW_GENOMIC_FILES;
```

### Phase 4: Gold Layer - Precision Oncology Analytics

* Build star schema with FACT_MOLECULAR_FINDINGS and dimensions for patient, gene, therapy, and tumor type.
* Implement cohort builders for eligibility and outcomes analysis.
* Snowpark ML models for response prediction and resistance pattern detection.

### Phase 5: Presentation and Clinical Integration

* Streamlit tumor board dashboards showing molecular profiles and therapy options.
* Research workbenches for cohort exploration and survival analysis.
* Controlled exports for regulatory submissions and publications.

## 9. Data Model Overview

### FACT: FACT_MOLECULAR_FINDINGS

* patient_id
* gene
* variant
* clinical_significance
* therapy_linked
* tumor_type
* report_ts

### Key Dimensions

* DIM_PATIENT (hashed)
* DIM_GENE
* DIM_THERAPY
* DIM_TUMOR_TYPE
* DIM_TIME

## 10. Advanced Analytics and ML

* **Variant Actionability Scoring**

  * Rank variants by evidence strength and therapeutic relevance.
* **Treatment Response Modeling**

  * Predict likelihood of response or resistance using molecular and clinical features.
* **Clinical Trial Matching**

  * Rule-based and ML-assisted matching against eligibility criteria.

## 11. Security, Privacy, and Ethical Controls

* Dynamic data masking for genomic identifiers.
* Row Level Security by study, facility, or consent scope.
* Consent-aware analytics to prevent unauthorized secondary use.
* Full lineage tracking for re-annotation audits.

## 12. Monitoring and Observability

* Pipeline freshness and annotation currency.
* Model performance drift monitoring.
* Data access audits for genomic assets.

## 13. Governance and Stewardship

* **Data Owner**: Molecular Pathology Director
* **Stewards**: Bioinformatics and Oncology Data Leads
* **Change Control**: Formal review for schema, annotation, or guideline updates.

## 14. Implementation Timeline

* **Month 0**: Governance, consent framework, and priority definition.
* **Month 1**: Bronze ingestion and Silver normalization.
* **Month 2**: Gold schema, cohort builders, initial Streamlit apps.
* **Month 3**: ML models, tumor board integration, production launch.

## 15. Risks and Mitigations

* **Rapid guideline evolution**

  * Mitigation: Immutable Bronze layer and re-annotation pipelines.
* **Data sensitivity**

  * Mitigation: Strict RBAC, masking, and consent enforcement.
* **Clinical adoption risk**

  * Mitigation: Co-design Streamlit apps with tumor board clinicians.

## 16. Acceptance Criteria

* Actionable variants identified for defined cancer cohorts.
* Streamlit dashboards adopted in tumor board workflows.
* Compliance validation completed with no high-risk findings.

## 17. Appendix

### Glossary

* NGS - Next Generation Sequencing
* VCF - Variant Call Format
* NCCN - National Comprehensive Cancer Network

### Communication Cadence

* Weekly oncology analytics standup.
* Monthly governance and compliance review.